20
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found
      Is Open Access

      Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Insufficient tissue oxygenation, or hypoxia, contributes to tumor aggressiveness and has a profound impact on clinical outcomes in cancer patients. At decreased oxygen tensions, hypoxia-inducible factors (HIFs) 1 and 2 are stabilized and mediate a hypoxic response, primarily by acting as transcription factors. HIFs exert differential effects on tumor growth and affect important cancer hallmarks including cell proliferation, apoptosis, differentiation, vascularization/angiogenesis, genetic instability, tumor metabolism, tumor immune responses, and invasion and metastasis. As a consequence, HIFs mediate resistance to chemo- and radiotherapy and are associated with poor prognosis in cancer patients. Intriguingly, perivascular tumor cells can also express HIF-2α, thereby forming a "pseudohypoxic" phenotype that further contributes to tumor aggressiveness. Therefore, therapeutic targeting of HIFs in cancer has the potential to improve treatment efficacy. Different strategies to target hypoxic cancer cells and/or HIFs include hypoxia-activated prodrugs and inhibition of HIF dimerization, mRNA or protein expression, DNA binding capacity, and transcriptional activity. Here we review the functions of HIFs in the progression and treatment of malignant solid tumors. We also highlight how HIFs may be targeted to improve the management of patients with therapy-resistant and metastatic cancer.

          Related collections

          Author and article information

          Journal
          Pharmacol. Ther.
          Pharmacology & therapeutics
          1879-016X
          0163-7258
          Aug 2016
          : 164
          Affiliations
          [1 ] Translational Cancer Research, Medicon Village 404:C3, Lund University, Lund, Sweden.
          [2 ] Translational Cancer Research, Medicon Village 404:C3, Lund University, Lund, Sweden. Electronic address: sven.pahlman@med.lu.se.
          Article
          S0163-7258(16)30055-9
          10.1016/j.pharmthera.2016.04.009
          27139518
          Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

          Comments

          Comment on this article